Breast Cancer

  • Jeffrey S. Ross
  • Gerald P. Linette
  • James Stec
  • Edward Clark
  • Mark Ayers
  • Fraser Symmans
  • Gabriel N. Hortobagyi
  • Lajos Pusztai


Based on current incidence rates, an American woman has a 1 in 9 chance of developing breast cancer at some time during her life.1 According to the American Cancer Societ Assistant y, in 2001, there were 192,200 new cases of invasive breast cancer and 47,100 cases of in situ disease in the United Profe States. That same year 40,200 American women died of the disease. This chapter considers the molecular pathology of breast cancer, focusing on the biomarker assays that are currently used in clinical management of the disease, excluding discussion of serum diagnostics, genetic predisposition testing, microarray-based RNA expression profiling, and micrometastasis detection, which are covered elsewhere in this book. The chapter concludes with a brief section on potential future assays, including the emerging field of pharmacogenomics.


Breast Cancer Epidermal Growth Factor Receptor Clin Oncol Metastatic Breast Cancer TP53 Mutation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Lacey JV Jr, Devesa SS, Brinton LA. Recent trends in breast cancer incidence and mortality. Environ Mol Mutagen. 2002;39:82–88.PubMedCrossRefGoogle Scholar
  2. 2.
    Hilsenbeck SG, Clark GM, McGuire WL. Why do so many prognostic factors fail to pan out? Breast Cancer Res Treat. 1992;22:197–206.PubMedCrossRefGoogle Scholar
  3. 3.
    Nicholoson S, Richard J, Sainsbury C, et al. Epidermal growth factor receptor (EGFR): results of a six-year follow-up study in operable breast cancer with emphasis on the node negative subgroup. Br J Cancer. 1991;63:146–150.Google Scholar
  4. 4.
    Castellani R, Visscher EW, Wykes S, et al. Interaction of transforming growth factor-alpha and epidermal growth factor receptor in breast carcinoma. Cancer. 1994;73:344–349.PubMedCrossRefGoogle Scholar
  5. 5.
    Tsutsui S, Kataoka A, Ohno S, et al. Prognostic and predictive value of epidermal growth factor receptor in recurrent breast cancer. Clin Cancer Res. 2002;8:3454–3460.PubMedGoogle Scholar
  6. 6.
    Ferrero JM, Ramaioli A, Largillier R, et al. Epidermal growth factor receptor expression in 780 breast cancer patients: a reappraisal of the prognostic value based on an eight-year median follow-up. Ann Oncol. 2001;12:841–846.PubMedCrossRefGoogle Scholar
  7. 7.
    Suo Z, Risberg B, Karlsson MG, et al. The expression of EGFR family ligands in breast carcinomas. Int J Surg Pathol. 2002;10:91–99.PubMedCrossRefGoogle Scholar
  8. 8.
    Morris C. The role of EGFR-directed therapy in the treatment of breast cancer. Breast Cancer Res Treat. 2002;(suppl 1):S51–S55.CrossRefGoogle Scholar
  9. 9.
    Solbach C, Roller M, Ahr A, et al. Anti-epidermal growth factor receptor-antibody therapy for treatment of breast cancer. Int J Cancer. 2002;101:390–394.PubMedCrossRefGoogle Scholar
  10. 10.
    Volas GH, Leitzel K, Teramoto Y, et al. Serial serum C-erbB-2 levels in patients with breast carcinoma. Cancer. 1996;78:267–272.PubMedCrossRefGoogle Scholar
  11. 11.
    Ross JS, Fletcher JA. HER-2/neu (c-erb-B2) gene and protein in breast cancer. Am J Clin Pathol. 1999;112(suppl 1):S53–S67.PubMedGoogle Scholar
  12. 12.
    Schnitt SJ, Jacobs TW. Current status of HER2 testing: caught between a rock and a hard place. Am J Clin Pathol. 2001;116:806–810.PubMedCrossRefGoogle Scholar
  13. 13.
    Hayes DF, Thor AD. c-erbB-2 in breast cancer: development of a clinically useful marker. Semin Oncol. 2002;29:231–245.PubMedCrossRefGoogle Scholar
  14. 14.
    Masood S, Bui MM. Prognostic and predictive value of HER2/neu oncogene in breast cancer. Microsc Res Tech. 2002;59:102–108.PubMedCrossRefGoogle Scholar
  15. 15.
    Paik S, Bryant J, Tan-Chiu E, et al. Real-world performance of HER2 testing—National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst. 2002;94:852–854.PubMedGoogle Scholar
  16. 16.
    Wang S, Saboorian MH, Frenkel EP, et al. Assessment of HER-2/neu status in breast cancer. Automated Cellular Imaging System (ACIS)-assisted quantitation of immunohistochemical assay achieves high accuracy in comparison with fluorescence in situ hybridization assay as the standard. Am J Clin Pathol. 2001;116:495–503.PubMedCrossRefGoogle Scholar
  17. 17.
    Wang S, Saboorian MH, Frenkel E, et al. Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays. J Clin Pathol. 2000;53:374–381.PubMedCrossRefGoogle Scholar
  18. 18.
    Tanner M, Gancberg D, Di Leo A, et al. Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am J Pathol. 2000;157:1467–1472.PubMedGoogle Scholar
  19. 19.
    Zhao J, Wu R, Au A, et al. Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma. Mod Pathol. 2002;15:657–665.PubMedCrossRefGoogle Scholar
  20. 20.
    Pawlowski V, Revillion F, Hornez L, et al. A real-time one-step reverse transcriptase-polymerase chain reaction method to quantify c-erbB-2 expression in human breast cancer. Cancer Detect Prev. 2000;24:212–223.PubMedGoogle Scholar
  21. 21.
    Bieche I, Onody P, Laurendeau I, et al. Real-time reverse transcription-PCR assay for future management of ERBB2-based clinical applications. Clin Chem. 1999;45:1148–1156.PubMedGoogle Scholar
  22. 22.
    Tubbs RR, Pettay JD, Roche PC, et al. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol. 2001;19:2714–2721.PubMedGoogle Scholar
  23. 23.
    Pawlowski V, Revillion F, Hebbar M, et al. Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription-polymerase chain reaction assay. Clin Cancer Res. 2000;6:4217–4225.PubMedGoogle Scholar
  24. 24.
    Huston JS, George AJ. Engineered antibodies take center stage. Hum Antibodies. 2001;10:127–142.PubMedGoogle Scholar
  25. 25.
    Hortobagyi GN. Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer. Semin Oncol. 2001;28:43–47.PubMedCrossRefGoogle Scholar
  26. 26.
    McKeage K, Perry CM. Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2. Drugs. 2002;62:209–243.PubMedCrossRefGoogle Scholar
  27. 27.
    Shawver LK, Slamon D, Ullrich A. Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell. 2002;1:117–123.PubMedCrossRefGoogle Scholar
  28. 28.
    Ligibel JA, Winer EP. Trastuzumab/chemotherapy combinations in metastatic breast cancer. Semin Oncol. 2002;29:38–43.PubMedGoogle Scholar
  29. 29.
    Roche PC, Ingle JN. Increased HER2 with U.S. Food and Drug Administration-approved antibody. J Clin Oncol. 1999;17:434.PubMedGoogle Scholar
  30. 30.
    Mass RD, Press MF, Anderson S, et al. Evaluation of clinical out-comes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin Breast Cancer. 2005;6:240–246.PubMedGoogle Scholar
  31. 31.
    Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20:719–726.PubMedCrossRefGoogle Scholar
  32. 32.
    Nichols DW, Wolff DJ, Self S, et al. A testing algorithm for determination of HER2 status in patients with breast cancer. Ann Clin Lab Sci. 2002;32:3–11.PubMedGoogle Scholar
  33. 33.
    Kobayashi M, Ooi A, Oda Y, et al. Protein overexpression and gene amplification of c-erbB-2 in breast carcinomas: a comparative study of immunohistochemistry and fluorescence in situ hybridization of formalin-fixed, paraffin-embedded tissues. Hum Pathol. 2002;33:21–28.PubMedCrossRefGoogle Scholar
  34. 34.
    Seidman AD, Fornier MN, Esteva FJ, et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol. 2001;19:2587–2595.PubMedGoogle Scholar
  35. 35.
    Schnitt SJ, Jacobs TW. Current status of HER2 testing: caught between a rock and a hard place. Am J Clin Pathol. 2001;116:806–810.PubMedCrossRefGoogle Scholar
  36. 36.
    Press MF, Slamon DJ, Flom KJ, et al. Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol. 2002;20:3095–3105.PubMedGoogle Scholar
  37. 37.
    Piccart M, Lohrisch C, Di Leo A, et al. The predictive value of HER2 in breast cancer. Oncology. 2001;(suppl 2):73–82.CrossRefGoogle Scholar
  38. 38.
    Dowsett M. Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer. Endocr Relat Cancer. 2001;8:191–195.PubMedCrossRefGoogle Scholar
  39. 39.
    Muss HB. Role of adjuvant endocrine therapy in early-stage breast cancer. Semin Oncol. 2001;28:313–321.PubMedCrossRefGoogle Scholar
  40. 40.
    Schmid P, Wischnewsky MB, Sezer O, et al. Prediction of response to hormonal treatment in metastatic breast cancer. Oncology. 2002;63:309–316.PubMedCrossRefGoogle Scholar
  41. 41.
    Nunes RA, Harris LN. The HER2 extracellular domain as a prognostic and predictive factor in breast cancer. Clin Breast Cancer. 2002;3:125–135.PubMedCrossRefGoogle Scholar
  42. 42.
    Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1-and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol. 2001;12:3808–3816.Google Scholar
  43. 43.
    Berns EM, Foekens JA, VanStaveren IL, et al. Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment. Gene. 1995;159:11–18.PubMedCrossRefGoogle Scholar
  44. 44.
    Sparano JA. Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials. Clin Breast Cancer. 2000;1:32–40.PubMedGoogle Scholar
  45. 45.
    Yu D. Mechanisms of ErbB2-mediated paclitaxel resistance and trastuzumab-mediated paclitaxel sensitization in ErbB2-overexpressing breast cancers. Semin Oncol. 2001;28(suppl 16):12–17.PubMedCrossRefGoogle Scholar
  46. 46.
    Kim R, Tanabe K, Uchida Y, et al. The role of HER-2 oncoprotein in drug-sensitivity in breast cancer. Oncol Rep. 2002;9:3–9.PubMedGoogle Scholar
  47. 47.
    Hamilton A, Larsimont D, Paridaens R, et al. A study of the value of p53, HER2, and Bcl-2 in the prediction of response to doxorubicin and paclitaxel as single agents in metastatic breast cancer: a companion study to EORTC 10923. Clin Breast Cancer. 2000;1:233–240.PubMedGoogle Scholar
  48. 48.
    Di Leo A, Larsimont D, Gancberg D, et al. HER-2 and topoisomerase llalpha as predictive markers in a population of nodepositive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide. Ann Oncol. 2001;12:1081–1089.PubMedCrossRefGoogle Scholar
  49. 49.
    Petit T, Borel C, Ghnassia JP, et al. Chemotherapy response of breast cancer depends on HER-2 status and anthracycline dose intensity in the neoadjuvant setting. Clin Cancer Res. 2001;7:1577–1581.PubMedGoogle Scholar
  50. 50.
    Harris LN, Yang L, Liotcheva V, et al. Induction of topoisomerase II activity after ErbB2 activation is associated with a differential response to breast cancer chemotherapy. Clin Cancer Res. 2001;7:1497–1504.PubMedGoogle Scholar
  51. 51.
    Lipton A, Ali SM, Leitzel K, et al. Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol. 2002;20:1467–1472.PubMedCrossRefGoogle Scholar
  52. 52.
    Voss A, Neumann R. Serum HER-2/neu: a new predictive marker. Int J Clin Pharmacol Ther. 2002;40:584–585.PubMedGoogle Scholar
  53. 53.
    Bose S, Lesser ML, Norton L, et al. Immunophenotype of intraductal carcinoma. Arch Pathol Lab Med. 1996;120:81–85.PubMedGoogle Scholar
  54. 54.
    Moreno A, Lioveras B, Figueras A, et al. Ductal carcinoma in-situ of the breast: correlation between histologic classification and biologic markers. Mod Pathol. 1997;10:1088–1092.PubMedGoogle Scholar
  55. 55.
    Mack L, Kerkzelit N, Doig G, et al. Relationship of a new histological categorization of ductal carcinoma in-situ of the breast with size and the immunohistochemical expression of p53, C-erb B2, bcl2 and ki-67. Hum Pathol. 1997;28:974–979.PubMedCrossRefGoogle Scholar
  56. 56.
    Wolber RA, DuPuis BA, Wick MR. Expression of cerb B2 oncoprotein in mammary and extramammary Paget’s disease. AM J Clin Pathol. 1991;96:243–247.PubMedGoogle Scholar
  57. 57.
    Fu W, Lobocki CA, Silberberg BK, et al. Molecular markers in Paget disease of the breast. J Surg Oncol. 2001;77:171–178.PubMedCrossRefGoogle Scholar
  58. 58.
    Masood S, Bui MM. Assessment of Her-2/neu overexpression in primary breast cancers and their metastatic lesions: an immunohistochemical study. Ann Clin Lab Sci. 2000;30:259–265.PubMedGoogle Scholar
  59. 59.
    Dittadi R, Zancan M, Perasole A, Gion M. Evaluation of HER-2/neu in serum and tissue of primary and metastatic breast cancer patients using an automated enzyme immunoassay. Int J Biol Markers. 2001;16:255–261.PubMedGoogle Scholar
  60. 60.
    Simon R, Nocito A, Hubscher T, et al. Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer. J Natl Cancer Inst. 2001;93:1141–1146.PubMedCrossRefGoogle Scholar
  61. 61.
    Vincent-Salomon A, Jouve M, Genin P, et al. HER2 Status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process. Cancer. 2002;94:2169–2173.PubMedCrossRefGoogle Scholar
  62. 62.
    Xu R, Perle MA, Inghirami G, et al. Amplification of Her-2/neu gene in Her-2/neu-overexpressing and-nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material. Mod Pathol. 2002;15:116–124.PubMedCrossRefGoogle Scholar
  63. 63.
    Joshi MG, Lee AK, Loda M, et al. Male breast carcinoma: an evaluation of prognostic factors contributing to a poorer outcome. Cancer. 1996;77:490–498.PubMedCrossRefGoogle Scholar
  64. 64.
    Pich A, Margaria E, Chiusa L, Oncogenes and male breast carcinoma: c-erbB-2 and p53 coexpression predicts a poor survival. J Clin Oncol. 2000;18:2948–2956.PubMedGoogle Scholar
  65. 65.
    Wang-Rodriguez J, Cross K, Gallagher S, et al. Male breast carcinoma: correlation of ER, PR, Ki-67, Her2-Neu, and p53 with treatment and survival, a study of 65 cases. Mod Pathol. 2002;15:853–861.PubMedCrossRefGoogle Scholar
  66. 66.
    Rayson D, Erlichman C, Suman VJ, et al. Molecular markers in male breast carcinoma. Cancer. 1998;83:1947–1955.PubMedCrossRefGoogle Scholar
  67. 67.
    Shpitz B, Bomstein Y, Sternberg A, et al. Angiogenesis, p53, and c-erbB-2 immunoreactivity and clinincopathological features in male breast cancer. J Surg Oncol. 2000;75:252–257.PubMedCrossRefGoogle Scholar
  68. 68.
    Bloom KJ, Govil H, Gattuso P, et al. Status of HER-2 in male and female breast carcinoma. Am J Surg. 2001;182:389–392.PubMedCrossRefGoogle Scholar
  69. 69.
    Stark A, Hulka BS, Joens S, et al. HER-2/neu amplification in benign breast disease and the risk of subsequent breast cancer. J Clin Oncol. 2000;18:267–274.PubMedGoogle Scholar
  70. 70.
    Jacobs TW, Gown AM, Yaziji H, et al. HER-2/neu protein expression in breast cancer evaluated by immunohistochemistry. A study of interlaboratory agreement. Am J Clin Pathol. 2000;113:251–258.PubMedCrossRefGoogle Scholar
  71. 71.
    Tubbs RR, Stoler MH. The quality of Her-2/Neu predictive immunohistochemistry: something FISHy? Mod Pathol. 2000;13:1–3.PubMedCrossRefGoogle Scholar
  72. 72.
    Liu MC, Gelmann EP. P53 gene mutations: case study of a clinical marker for solid tumors. Semin Oncol. 2002;29:246–257.PubMedCrossRefGoogle Scholar
  73. 73.
    Gasco M, Shami S, Crook T. The p53 pathway in breast cancer. Breast Cancer Res. 2002;4:70–76.PubMedCrossRefGoogle Scholar
  74. 74.
    Cunningham JM, Ingle JN, Jung SH, et al. p53 gene expression in node positive breast cancer: relationship to DNA ploidy and prognosis. J Nat Cancer Inst. 1994;86:1871–1873.PubMedCrossRefGoogle Scholar
  75. 75.
    Lohmann D, Ruhri C, Schmitt M, et al. Accumulation of p53 protein as an indicator for p53 gene mutation in breast cancer. Diagn Mol Pathol. 1993;2:36–41.PubMedGoogle Scholar
  76. 76.
    Bhargava V, Thor A, Deng G, et al. The association of p53 immunopositivity with tumor proliferation and other prognostic indicators in breast cancer. Modern Pathol. 1994;7:361–368.Google Scholar
  77. 77.
    Rosanelli GP, Steindorfer P, Wirnsberger GH, et al. Mutant p53 expression and DNA analysis in human breast cancer. Comparison with conventional clinicopathological parameters. Anticancer Res. 1995;15:581–586.PubMedGoogle Scholar
  78. 78.
    Pelosi G, Bresaola E, Rodella S, et al. Expression of proliferating cell nuclear antigen, Ki-67 antigen, estrogen receptor protein, and tumor suppressor p53 gene in cytologic samples of breast cancer: an immunochemical study with clinical, pathobiological, and histologic correlations. Diagn Cytopathol. 1994;11:131–140.PubMedCrossRefGoogle Scholar
  79. 79.
    Beck T, Weller EE, Weikel W, et al. Usefulness of immunohistochemical staining for p53 in the prognosis of breast carcinomas: correlation with established prognosis parameters and with the proliferation marker, MIB-1. Gynecol Oncol. 1995;57:96–104.PubMedCrossRefGoogle Scholar
  80. 80.
    Peyrat J-P, Bonneterre J, Lubin R, et al. Prognostic significance of circulating P53 antibodies in patients undergoing surgery for local regional breast cancer. Lancet. 1995;345:621–622.PubMedCrossRefGoogle Scholar
  81. 81.
    Daidone MG, Veneroni S, Benini E, et al. Biological markers as indicators of response to primary and adjuvant chemotherapy in breast cancer. Int J Cancer. 1999;84:580–586.PubMedCrossRefGoogle Scholar
  82. 82.
    Kandioler-Eckersberger D, Ludwig C, et al. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin Cancer Res. 2000;6:50–56.PubMedGoogle Scholar
  83. 83.
    Bertheau P, Plassa F, Espie M, et al. Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy. Lancet. 2002;360:852–854.PubMedCrossRefGoogle Scholar
  84. 84.
    Sjostrom J, Blomqvist C, Heikkila P, et al. Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer. Clin Cancer Res. 2000;6:3103–3110.PubMedGoogle Scholar
  85. 85.
    Palmieri C, Cheng GJ, Saji S, et al. Estrogen receptor beta in breast cancer. Endocr Relat Cancer. 2003;9:1–13.CrossRefGoogle Scholar
  86. 86.
    Nilsson S, Gustafsson JA. Biological role of estrogen and estrogen receptors. Crit Rev Biochem Mol Biol. 2002;37:1–28.PubMedCrossRefGoogle Scholar
  87. 87.
    Sommer S, Fuqua SA. Estrogen receptor and breast cancer. Semin Cancer Biol. 2001;11:339–352.PubMedCrossRefGoogle Scholar
  88. 88.
    Osbome CK. Steroid hormone receptors in breast cancer management. Breast Cancer Res Treat. 1998;51:227–238.CrossRefGoogle Scholar
  89. 89.
    Locker GY. Hormonal therapy of breast cancer. Cancer Treat Rev. 1998;24:221–240.PubMedCrossRefGoogle Scholar
  90. 90.
    Wilbur DC, Willis J, Mooney RA, et al. Estrogen and progesterone detection in archival formalin-fixed paraffin embedded tissue from breast carcinoma: a comparison of immunocytochemistry with dextran coated charcoal assay. Modern Pathol. 1992;5:79–84.Google Scholar
  91. 91.
    Esteban JM, Battifora H, Warsi Z, et al. Quantitation of estrogen receptors on paraffin-embedded tumors by image analysis. Modern Pathol. 1991;4:53–57.Google Scholar
  92. 92.
    Jordan VC. Tamoxifen: a most unlikely pioneering medicine. Nat Rev Drug Discov. 2003;2:205–213.PubMedCrossRefGoogle Scholar
  93. 93.
    Schmid P, Wischnewsky MB, Sezer O, et al. Prediction of response to hormonal treatment in metastatic breast cancer. Oncology. 2002;63:309–316.PubMedCrossRefGoogle Scholar
  94. 94.
    Clemons M, Danson S, Howell A. Tamoxifen (“Nolvadex”): a review. Cancer Treat Rev. 2002;28:165–180.PubMedCrossRefGoogle Scholar
  95. 95.
    Ibrahim NK, Hortobagyi GN. The evolving role of specific estrogen receptor modulators (SERMs) Surg Oncol. 1999;8:103–123.PubMedCrossRefGoogle Scholar
  96. 96.
    Miller WR, Anderson TJ, Dixon JM. Anti-tumor effects of letrozole. Cancer Invest. 2002;20:15–21.PubMedCrossRefGoogle Scholar
  97. 97.
    Buzdar AU, Robertson JF, Eiermann W, et al. An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane. Cancer. 2002;95:2006–2016.PubMedCrossRefGoogle Scholar
  98. 98.
    Taylor JG, et al. Using genetic variation to study human disease. Trends Mol Med. 2001;7:507–512.PubMedCrossRefGoogle Scholar
  99. 99.
    Weber W, Estoppey J, Stoll H. Familial cancer diagnosis. Anticancer Res. 2001;21:3631–3635.PubMedGoogle Scholar
  100. 100.
    Ingelman-Sundberg M. Genetic susceptibility to adverse effects of drugs and environmental toxicants. The role of the CYP family of enzymes. Mutat Res. 2001;482:11–19.PubMedGoogle Scholar
  101. 101.
    Innocenti F, Ratain MJ. Update on pharmacogenetics in cancer chemotherapy. Eur J Cancer. 2002;38:639–644.PubMedCrossRefGoogle Scholar
  102. 102.
    Roses AD. Pharmacogenetics. Hum Mol Genet. 2001;10:2261–2267.PubMedCrossRefGoogle Scholar
  103. 103.
    Relling MV, Dervieux T. Pharmacogenetics and cancer therapy. Nat Rev Cancer. 2001;1:99–108.PubMedCrossRefGoogle Scholar
  104. 104.
    Nishimura R, Nagao K, Miyayama H, et al. Thymidylate synthase levels as a therapeutic and prognostic predictor in breast cancer. Anticancer Res. 1999;19:5621–5626.PubMedGoogle Scholar
  105. 105.
    Weinstein JN. Pharmacogenomics—teaching old drugs new tricks. N Engl J Med. 2000;343:1408–1409.PubMedCrossRefGoogle Scholar
  106. 106.
    Slonim DK. Transcriptional profiling in cancer: the path to clinical pharmacogenomics. Pharmacogenomics. 2001;2:123–136.PubMedCrossRefGoogle Scholar
  107. 107.
    Ayers M, Symmans WF, Stec J, et al. Gene expression profiling of fine needle aspirations of breast cancer identifies genes associated with complete pathologic response to neoadjuvant taxol/FAC chemotherapy [abstract 220]. Breast Cancer Res Treat. 2002;76: S64.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Jeffrey S. Ross
    • 1
  • Gerald P. Linette
    • 2
  • James Stec
    • 3
  • Edward Clark
    • 4
  • Mark Ayers
    • 4
  • Fraser Symmans
    • 5
  • Gabriel N. Hortobagyi
    • 6
    • 7
  • Lajos Pusztai
    • 6
    • 7
  1. 1.Department of Pathology and Laboratory MedicineAlbany Medical CollegeAlbanyUSA
  2. 2.Department of Internal Medicine and NeurosurgeryWashington University School of MedicineSt LouisUSA
  3. 3.Abbott LabsChicagoUSA
  4. 4.Bristol-Myers Squibb CompanyPrincetonUSA
  5. 5.University of Texas MD Anderson Cancer CenterHoustonUSA
  6. 6.Department of MedicineUniversity of Texas M.D. Anderson Cancer CenterHoustonUSA
  7. 7.Department of Breast Medical OncologyUniversity of Texas M.D. Anderson Cancer CenterHoustonUSA

Personalised recommendations